Patents Assigned to Sekisui Medical Co., Ltd.
  • Patent number: 11275085
    Abstract: A problem of the present invention is to provide an immunochromatographic test strip avoiding agglutination of colloidal gold while red blood cells in whole blood are agglutinated and then separated and removed in the case of using polybrene as a hemagglutinating agent and the colloidal gold conjugates as a detection reagent, and to provide immunochromatography using the test strip. To solve the problem, the present inventors reviewed the composition of the existing reagent itself from a completely different viewpoint rather than the selection of type or amount of polyanions, and as a result of extensive study on each element, the inventors surprisingly found that agglutination of colloidal gold may be suppressed by using a particular additive without neutralization by polyanions.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: March 15, 2022
    Assignee: SEKISUI MEDICAL CO., LTD.
    Inventors: Keigo Kohno, Mayumi Yoshida, Mitsuaki Yamamoto, Shinya Yokokawa, Marie Asami
  • Patent number: 11255756
    Abstract: A testing vessel 1 includes a flexible vessel body 10 having a bottom and a hollow shape; and a partition 11 axially extending in the vessel body 10 and dividing an analyte extract containable space 50 in the vessel body 10 into two or more compartments. The testing vessel 1 enables two or more items to be readily tested with two or more test pieces.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: February 22, 2022
    Assignee: SEKISUI MEDICAL CO., LTD.
    Inventors: Kazunori Saito, Hiroyuki Oono, Kimiyoshi Nishitani, Motoki Morita, Shinji Matsuura, Hiroshi Yashiro
  • Publication number: 20220049284
    Abstract: The present invention provides a method of detecting and a method of quantifying oligonucleotides with more excellent specificity and quantitativity as compared to conventional signal amplification (PALSAR) measurement methods. In the present invention, the problem is solved by hybridizing a target oligonucleotide to be measured with a complementary nucleic acid probe (3?-complementary sequence of target sequence-5?), or hybridizing the target oligonucleotide to be measured having given bases such as poly(A) added thereto with a complementary nucleic acid probe (3?-complementary sequence of target oligonucleotide+complementary sequence of given bases-5?), decomposing and removing an incomplete hybridization product by using a single-strand-specific nuclease such as Si nuclease, and measuring the nucleic acid probe contained in a remaining complete hybridization product by a PALSAR method.
    Type: Application
    Filed: September 10, 2019
    Publication date: February 17, 2022
    Applicant: SEKISUI MEDICAL CO., LTD.
    Inventors: Akane OOMORI, Koichi SHIBUSAWA
  • Publication number: 20220033911
    Abstract: Provided are a method for determining prognosis of endometrial cancer, a method for determining endometrial cancer patient compatible to preservation therapy, and a method for determining risk of endometrial cancer. The methods comprise detecting DNA methylation level at a target CpG site in a genomic DNA derived from an endometrial cell, endometrial cancer cell or tissue containing the cell. Prognosis of endometrial cancer, compatibility to preservation therapy, or risk of endometrial cancer of a subject is determined on the basis of the detected DNA methylation level.
    Type: Application
    Filed: December 5, 2019
    Publication date: February 3, 2022
    Applicants: KEIO UNIVERSITY, SEKISUI MEDICAL CO., LTD.
    Inventors: Yae KANAI, Eri ARAI, Daisuke AOKI, Nobuyuki SUSUMU, Wataru YAMAGAMI, Takeshi MAKABE
  • Publication number: 20220011306
    Abstract: A problem to be solved is to provide an immunochromatographic test strip in which a specimen sufficiently and quickly permeates into a sample application region within a test time so that variations in detection values of a test line can be prevented. Particularly, a problem to be solved is to provide an immunochromatographic test strip causing less variations in detection values even when the specimen is whole blood. The problems are solved by providing an immunochromatographic test strip including at least a sample application region, a development region, and a detection region, wherein the sample application region contains polyethylene glycol having a molecular weight of 15,000 to 700,000.
    Type: Application
    Filed: November 19, 2018
    Publication date: January 13, 2022
    Applicant: SEKISUI MEDICAL CO., LTD.
    Inventors: Keigo KOHNO, Kanako ITOU, Shun SAKAI, Akira NAKAJIMA, Motoki MORITA
  • Publication number: 20220011220
    Abstract: A light generator including a light source, an optical switch that controls ON/OFF of light from the light source, and a mirror that reflects light from the optical switch and sends the light back to the optical switch. A light generator less in residue in fitting of a ring-down signal, and a radioactive carbon dioxide isotope analysis device and a radioactive carbon dioxide isotope analysis method, by use of the light generator are provided.
    Type: Application
    Filed: November 21, 2019
    Publication date: January 13, 2022
    Applicants: SEKISUI MEDICAL CO., LTD., NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM
    Inventors: Kenji YOSHIDA, Shin-ichi NINOMIYA, Hideki TOMITA, Tetsuo IGUCHI, Norihiko NISHIZAWA, Volker SONNENSCHEIN, Ryohei TERABAYASHI
  • Publication number: 20220011221
    Abstract: A carbon isotope analysis method, including the steps of: generating carbon dioxide isotope from carbon isotope; feeding the carbon dioxide isotope into an optical resonator having a pair of mirrors; applying irradiation light having an absorption wavelength of the carbon dioxide isotope into the optical resonator; adjusting a relative positional relationship between the mirrors so that an optical axis of the irradiation light and an optical axis of light generated by the etalon effect are not matched; measuring the intensity of the transmitted light generated by resonance of carbon dioxide isotope excited by the irradiation light; and calculating the concentration of the carbon isotope from the intensity of the transmitted light. An optical resonator that can be suppressed in the parasitic etalon effect, and a carbon isotope analysis device and a carbon isotope analysis method, by use of the optical resonator, are provided.
    Type: Application
    Filed: November 21, 2019
    Publication date: January 13, 2022
    Applicants: SEKISUI MEDICAL CO., LTD., NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM
    Inventors: Kenji YOSHIDA, Shin-ichi NINOMIYA, Hideki TOMITA, Tetsuo IGUCHI, Norihiko NISHIZAWA, Volker SONNENSCHEIN, Ryohei TERABAYASHI
  • Patent number: 11221325
    Abstract: To provide a device for concentration and separation of circulating tumor cells, capable of recovering circulating tumor cells in a blood-derived specimen simply, at a high recovery rate, and with low invasion of the tumor cells. A device for concentration and separation of circulating tumor cells present in a blood-derived specimen, in which a cell separating agent with thixotropic property having a specific gravity ranging from 1.050 to 1.080 and enabling the separation of tumor cells and blood cells other than the tumor cells by a centrifugal operation is housed in a bottomed tube-shaped container closed at one end and opened at the other end.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: January 11, 2022
    Assignee: SEKISUI MEDICAL CO., LTD.
    Inventors: Ryusuke Okamoto, Tomonori Inoue
  • Patent number: 11220704
    Abstract: Provided is a method of avoiding the influence of a coexisting substance in the measurement of HbA1c % for a whole blood sample by an enzymatic method. Specifically, provided is a method of measuring a ratio of a hemoglobin A1c concentration to a hemoglobin concentration in a sample by an enzymatic method, the method including: a first step of optically measuring the hemoglobin concentration; and a second step of optically measuring the hemoglobin A1c concentration, wherein, when HbA1c % is calculated by dividing the hemoglobin A1c concentration measured in the second step by the hemoglobin concentration measured in the first step, the hemoglobin concentration serving as a denominator, which is measured at a first wavelength, is corrected using a result measured at a second wavelength.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: January 11, 2022
    Assignee: SEKISUI MEDICAL CO., LTD.
    Inventors: Satoshi Machida, Tomohisa Nishio, Kazuo Nakanishi
  • Publication number: 20210405072
    Abstract: A method for controlling MNPT is required. Coexistence of a specific metal ion with tissue thromboplastin enables MNPT to be controlled/adjusted to a desired time. Coexistence of the specific metal ion with tissue thromboplastin also enables improvement of stability when a thromboplastin reagent is stored in a solution form.
    Type: Application
    Filed: September 25, 2019
    Publication date: December 30, 2021
    Applicant: SEKISUI MEDICAL CO., LTD.
    Inventors: Kengo OONISHI, Yoshimasa BANBA, Tomohisa NISHIO
  • Publication number: 20210396741
    Abstract: There is provided a method for preventing an occurrence of an irregular detection value and performing measurement with good reproducibility in an immunoassay using an automatic analyzer regardless of whether the reaction cuvette used is of a disposable type or a reusable type and whether the optical detection method used measures transmitted light or scattered light. There is also provided an immunoassay reagent for use in the method. A method for preventing the occurrence of irregular detection and enhancing the reproducibility of measurement includes using a reagent containing polyethylene glycol or the like having a weight-average molecular weight of 300 to 3000.
    Type: Application
    Filed: November 8, 2019
    Publication date: December 23, 2021
    Applicant: SEKISUI MEDICAL CO., LTD.
    Inventors: Tadaaki YOSHIDA, Chihiro MIZUNIWA, Shinichiro KITAHARA, Hiroshi TAKAHASHI
  • Publication number: 20210389306
    Abstract: A problem to be solved is to provide a glycated hemoglobin (%) assay method and assay reagent capable of accurate measurement of glycated hemoglobin (%) in blood even when a blood specimen containing hemoglobin contains abnormal hemoglobin such as HbS or HbC. The present invention provides a method capable of accurate measurement of glycated hemoglobin (%) in blood even in a specimen containing abnormal hemoglobin by combining two types of monoclonal antibodies, i.e., an anti-glycated hemoglobin monoclonal antibody and a monoclonal antibody to the anti-glycated hemoglobin monoclonal antibody, and an assay reagent for performing the method.
    Type: Application
    Filed: September 27, 2019
    Publication date: December 16, 2021
    Applicant: SEKISUI MEDICAL CO., LTD.
    Inventors: Mieko OTA, Osamu MIYAZAKI, Satoko SEO, Mitsuaki YAMAMOTO, Tomohisa NISHIO
  • Publication number: 20210389326
    Abstract: A method and a diagnostic agent kit for detecting viral liver cancer having excellent sensitivity and specificity are provided. The problem can be solved by a method for detecting viral liver cancer, comprising measuring an amount of free AIM in a biological sample from a subject and comparing the measured amount of free AIM with a reference value.
    Type: Application
    Filed: November 8, 2019
    Publication date: December 16, 2021
    Applicants: SEKISUI MEDICAL CO., LTD., SOCIAL WELFARE ORGANIZATION "SAISEIKAI" IMPERIAL GIFT FOUNDATION INC.
    Inventors: Toru MIYAZAKI, Tomoko YAMAZAKI, Takeshi OKANOUE, Tomohide ASAI, Yuka KANETSUKI, Jiro HIROTA
  • Publication number: 20210382041
    Abstract: An object of the present invention is to provide a measurement method and a reagent for measurement which can measure LRG in a biological sample simply in a short time. The present inventors have intensively studied to achieve the object and made findings that LRG in a biological sample can be measured simply in a short time by an immunoagglutination measurement method in which the biological sample is brought into contact with insoluble carrier particles carrying a first anti-LRG monoclonal antibody and insoluble carrier particles carrying a second anti-LRG monoclonal antibody in a liquid phase, and the invention has been thus completed.
    Type: Application
    Filed: October 8, 2019
    Publication date: December 9, 2021
    Applicants: SEKISUI MEDICAL CO., LTD., NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION
    Inventors: Shigeo TAKAYAMA, Tetsuji NAKA, Satoshi SERADA
  • Publication number: 20210349085
    Abstract: A problem to be solved is to provide a test strip capable of avoiding occurrence of a so-called bleaching phenomenon in an immunochromatographic test strip to enable better detection and visibility. Another problem to be solved is to provide an immunochromatographic test strip capable of preventing a variation in detection value on a test line. The problems are solved by an immunochromatographic test strip including at least a porous membrane and having a sample application region, a development region, and a detection region in which a specific binding substance is immobilized, wherein the detection region is immobilized on a front surface of the porous membrane, and wherein an opaque base material having a thickness of 30 ?m or more and 200 ?m or less is placed on the back surface of the porous membrane.
    Type: Application
    Filed: September 26, 2019
    Publication date: November 11, 2021
    Applicant: SEKISUI MEDICAL CO., LTD.
    Inventors: Shun SAKAI, Keigo KOHNO, Kanako ITOU, Akira NAKAJIMA, Motoki MORITA
  • Publication number: 20210333295
    Abstract: Excellent analysis of a coagulation characteristic of a blood sample is implemented. A method for analyzing a coagulation characteristic of a blood specimen according to the present invention includes: acquiring data for a coagulation reaction curve indicating a coagulation reaction amount of a mixed solution containing a blood sample and a reagent with respect to reaction time; calculating data for a differential curve obtained by differentiating the coagulation reaction curve; calculating information related to a center-of-gravity point of the differential curve; and evaluating the coagulation characteristic of the blood sample using the information related to the center-of-gravity point.
    Type: Application
    Filed: November 15, 2019
    Publication date: October 28, 2021
    Applicant: SEKISUI MEDICAL CO., LTD.
    Inventors: Toshiki KAWABE, Yukio ODA
  • Patent number: 11155805
    Abstract: An object of the present invention is to provide an efficient nucleic acid recovery method capable of concentrating a nucleic acid from a sample containing a nucleic acid such that the nucleic acid is usable in gene amplification reaction. To solve the problem, the present inventors have found that by targeting a protein to which a nucleic acid is bound (hereinafter also referred to as a nucleoprotein or a protein-nucleic acid complex) rather than targeting the nucleic acid itself, or specifically, by causing a specific antibody against the protein to act, the nucleic acid can be captured simultaneously with the protein, and thereby completing the present invention. Furthermore, the present inventors have found that if animal cells, bacteria, viruses, etc.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: October 26, 2021
    Assignee: SEKISUI MEDICAL CO., LTD.
    Inventors: Hiroyuki Ebinuma, Katsura Uchida
  • Patent number: 11142801
    Abstract: It is intended to provide a method for determining a tumor. The method for determining a tumor comprises: (1) treating genomic DNA prepared from a subject tissue or cell with bisulfite (the subject tissue or cell is derived from a patient who is affected by a tumor and is determined as (i) having MSI-H of the tumor in MSI examination and/or no or reduced expression of MLH1 in the tumor in immunohistochemical examination, and (ii) having no mutation in MLH1 in genetic examination); 2) amplifying, by PCR, DNA comprising a portion or the whole of MLH1 promoter region from the bisulfite-treated DNA; 3) subjecting the PCR amplification product to ion exchange chromatography to obtain a detection signal; 4) determining whether or not the peak of the detection signal is a peak indicating highly methylated DNA; and 5) determining the tumor as a tumor derived from a patient without Lynch syndrome when the peak is determined as a peak indicating highly methylated DNA.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: October 12, 2021
    Assignees: JAPANESE FOUNDATION FOR CANCER RESEARCH, SEKISUI MEDICAL CO., LTD.
    Inventors: Masami Arai, Sachio Nomura, Yuriko Nemoto, Takuya Yotani
  • Publication number: 20210302426
    Abstract: An object of the present invention is to provide an immunological detection method comprising carrying out an immunoreaction using an antibody to Mycoplasma pneumoniae protein P30, in which Mycoplasma pneumoniae is detected with high sensitivity. Provided is an immunological detection method for Mycoplasma pneumoniae using an antibody to Mycoplasma pneumoniae protein P30, the method comprising carrying out an immunoreaction in the presence of a polyoxyethylene alkyl amine. The immunological detection method that uses immunochromatography is also provided.
    Type: Application
    Filed: August 5, 2019
    Publication date: September 30, 2021
    Applicant: SEKISUI MEDICAL CO., LTD.
    Inventors: Yasushi OCHIAI, Tomofumi NAKAMURA
  • Publication number: 20210293806
    Abstract: A problem to be solved by the present invention is to provide an immunochromatographic test strip capable of avoiding so-called blank color development in an immunochromatographic test strip and enabling more accurate determination by an approach different from the prior arts. The present invention provides an immunochromatographic test strip comprising: at least a sample application region, a development region, and a detection region in which an antibody is immobilized, wherein the detection region includes the antibody and one or more saccharides selected from the group consisting of a reductive monosaccharide and a reductive disaccharide.
    Type: Application
    Filed: October 21, 2019
    Publication date: September 23, 2021
    Applicant: SEKISUI MEDICAL CO., LTD.
    Inventors: Akira NAKAJIMA, Kanako ITOU, Keigo KOHNO, Shun SAKAI, Motoki MORITA